… differences between the two most common EGFR mutations, we retrospectively analysed
RR and survival of advanced NSCLC patients harbouring either the exon 19 deletion or L858R …

… to compare the clinical outcomes of gefitinib-treated and erlotinib-treated patients with
advanced/metastatic or recurrent NSCLC harboring an EGFR mutation in either exon 19 or 21. …

… patients with either 19 or 21 exon alterations, patient characteristics (age, sex, ethnicity,
smoking status; tumour histology; Eastern Cooperative Oncology Group performance status) and …

… Conclusions: Non-LRE deletions in exon 19 were associated with worse … clinical outcome
under EGFR TKIs depends on not only the existence but also the types of deletions in exon 19. …

… Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20
insertion (… We conducted a retrospective cohort study to assess the clinical outcomes of EGFR …

… exon 19 and exon 21 mutations. , 15 This study investigated the differential clinical outcomes
… B, PFS for patients with either exon 19 deletion or L858R mutation. C, PFS for patients with …

… 44 will result in a significantly better outcome than skipping of exon 46. Similarly, our data
suggest that multiexon skipping of either exons 46 to 47 or 46 to 48 is likely to result in a better …

… ) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation
(… This study aimed to investigate the clinical outcomes of EGFR-TKI treatment in patients with …

… In the FLAURA study that compared osimertinib with either erlotinib or gefitinib in previously
… other clinical outcomes in the three patient groups described above. Clinical outcomes of …

… found to have either EGFR exon 19 deletion or EGFR L858R. The clinical characteristics of
… as predictors of clinical outcomes in Japanese patients with recurrent non-small-cell lung …